[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prophylaxis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prophylaxis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,56,82,105,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053936","phase-1-cabotegravir-hormone-pkpd-interactions-for-hiv-prevention-100053936",false,"NCT07672717","Cabotegravir-Hormone PK\u002FPD Interactions for HIV Prevention","CHIPP-PrEP: Cabotegravir-Hormone Interrogation of Pharmacokinetics\u002FPharmacodynamics (PK\u002FPD) for HIV Prevention","CHIPP-PrEP","Inclusion Criteria:\n\n* 19 years of age or older\n* For persons using exogenous hormones, must be on a stable regimen for ≥6 months and remain on that regimen throughout study conduct, and exogenous hormone regimens must be prescribed and managed under the care of a healthcare professional\n* For females, must be on a non-hormonal contraceptive agent, and must persist in contraceptive use for the duration of the study\n* Body weight greater than 35 kg (77.2 lbs)\n* HIV-1 uninfected at screening and enrollment as documented by an instrumented Ag\u002FAb assay and HIV-1 RNA testing\n* Understand and agree to local STI reporting requirements\n* Willing to abstain from additional antiretroviral agents (including PrEP agents, F\u002FTAF and F\u002FTDF) during the duration of the study\n* Willing to abstain from insertion of anything (drug, enema, penis, or sex toy) in the rectum or vagina for 72 hours before and 72 hours after each flexible sigmoidoscopy\n* Willing to refrain from aspirin and NSAID use for one week before and after each study biopsy visit\n* Willing and able to use condoms for all receptive anal intercourse and receptive vaginal intercourse for the duration of study participation\n* Able and willing to communicate in English\n* Able and willing to provide written informed consent to take part in the study\n* Able and willing to provide adequate information for locator purposes\n* Availability to return for all study visits, barring unforeseen circumstances\n* Agree not to participate in other research studies involving drugs and\u002For medical devices for the duration of the study\n\nExclusion Criteria:\n\n* History of previous long-acting antiretroviral use, including CAB-LA and long-acting lenacapavir\n* History of oral PrEP (F\u002FTDF, F\u002FTAF) use within the prior eight weeks\n* For females, if a participant is pregnant or plans to become pregnant during study duration\n* For females, if the participant is actively breastfeeding\n* For females, if the participant is post-menopausal or accessing exogenous hormone replacement therapy\n* For females, has irregular menstrual cycles\n* Has a tattoo or other dermatological condition which may interfere with product administration or interpretation of injection site reactions\n* Surgically-placed or injected buttock implants or filler, per self-report\n* One or more reactive or positive HIV test results at screening or enrollment, even if HIV infection is not confirmed\n* Current known HIV-infected partner(s)\n* Symptoms suggestive of acute HIV seroconversion at screening and enrollment\n* Known or suspected allergy to CAB-LA\n* Any ≥ Grade 2 laboratory abnormality at baseline as defined by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 - July 2017, and Addendum 3 (Rectal Grading Tables for Use in Microbicide Studies)\n* Significant rectal symptom(s) as determined by medical history or by participant self-report (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, history of inflammatory bowel disease, presence of symptomatic hemorrhoids, and presence of any painful anorectal conditions that would be tender to manipulation)\n* At screening or within the past 2 months: participant-reported symptoms and\u002For clinical or laboratory diagnosis of active rectal or genital infection requiring treatment per current CDC guidelines or symptomatic urinary tract infection (UTI). Infections requiring treatment include chlamydia (CT), gonorrhea (GC), syphilis, active HSV lesions, chancroid, genital sores or ulcers, and, if clinically indicated, genital warts. HSV seropositivity with no active genital lesions is not an exclusion criterion. (Note: if an STI apart from HIV is detected, the participant will be referred for treatment and can be retested in 30 days and re-screened once.)\n* History of significant gastrointestinal bleeding\n* Clinically significant cardiovascular disease, as defined by history of symptomatic arrhythmia, ischemia, or other significant cardiac disease\n* Current use of warfarin or heparin or other anticoagulant medications associated with increased risk for bleeding following mucosal biopsy (e.g., daily high dose aspirin \\[\\>81 mg\\], NSAIDs, or Pradaxa®)\n* Use of systemic or anorectal immunomodulatory medications within 4 weeks of enrollment or planned use at any time during study participation\n* Per participant report, use of any rectally or vaginally administered products containing N-9 (including condoms) or investigational products within 4 weeks of enrollment, or planned use of either at any time during study participation\n* Any other condition or prior therapy that, in the opinion of the investigator, would preclude informed consent, make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements.\n* Individuals with neocervix will be excluded from giving cervical biopsies, if eligible for study participation.",true,"ALL","19 Years",{"count":21,"type":22},32,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a research study to better understand how long-acting cabotegravir (CAB-LA) works to prevent HIV in people. This study will also evaluate the impact of endogenous and therapeutic hormones on CAB-LA pharmacology. The investigators will also evaluate if participants experience any medical problems when taking CAB-LA.",[28,29,30],"HIV","Prophylaxis","Injectable","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2026-07-07",{"date":39,"type":22},"2031-12",{"name":41,"class":42},"Johns Hopkins University","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":23,"phases":47,"briefSummary":26,"conditions":48,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":55,"locationsCount":43},"100644787",{"count":21,"type":22},[25],[28,29,30],"2026-06-26",{"date":51,"type":35},"2026-06-30",{"date":53,"type":22},"2026-07",{"date":39,"type":22},{"name":41,"class":42},{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":18,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100600779","monitoring-of-anti-tfpi-in-hemophilia-100600779","NCT07101926","Monitoring of Anti-TFPI in Hemophilia","Monitoring of Anti-TFPI in Hemophilia EUREKA","EUREKA","* Inclusion Criteria :\n\n  * \\- Male Patient\n  * 18 years old\n  * severe hemophilia patients A or B (FVIII \\\u003C 1%,FIX\\\u003C=2%)\n  * on prophylaxis with FVIII or IX concentrates after an adequate washout period of 48h for SHL FVIII molecules, at least 4 days for EHL-FVIII Fc and at least 10 days for EHL-FIX molecules.\n  * On prophylaxis with Marstacimab\n  * Willing to participate\n  * Capable of following protocol procedures under investigator appreciation\n* Exclusion Criteria :\n\n  * \\- patients refusing to provide 4 additional blood tubes for research\n  * Patient with an other coagulation disorder\n  * patients who received an injection of FVIII or FIX during the required washout period","18 Years",{"count":66,"type":22},11,"OBSERVATIONAL","During the development of anti-TFPI antibodies, thrombin generation assay (TGA) was employed using both in vitro measurements (antibodies added to blood samples) and ex vivo approaches (blood samples from patients in phase II and III trials). While a significant improvement in thrombin generation was observed in all samples from patients with severe hemophilia, no correlation with clinical outcomes could be established. Notably, thrombin peak levels were consistently improved even in patients who experienced bleeding episodes. These measurements were conducted in platelet-poor plasma (PPP) with standard reagents, which may not adequately reflect the hemostatic efficacy of anti-TFPI antibodies given their mechanism of action. It is hypothesized that optimizing reagents and utilizing more appropriate biological materials could enhance TGA sensitivity, as previously demonstrated for monitoring emicizumab.\n\nThe absence of a laboratory assay to monitor anti-TFPI (tissue factor pathway inhibitor) antibodies poses a significant challenge for managing patients in surgical settings and treating acute severe bleeding. This study aims to develop a reliable assay to evaluate the hemostatic efficacy of anti-TFPI antibodies and their combined procoagulant effect with factor concentrates (FVIII or FIX) or bypassing agents.",[70,71,29],"Hemophilia","Rebalancing Agents","2026-03-19",{"date":74,"type":35},"2026-03-23",{"date":76,"type":35},"2025-10-23",{"date":78,"type":22},"2026-08",{"name":80,"class":42},"Hospices Civils de Lyon",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":18,"minAge":64,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":43},"100611734","post-ercp-pancreatitis---prophylactic-measures-implementation-study-pep-promis-100611734","NCT07244432","Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS)","Post-ERCP Pancreatitis- Prophylactic Measures Implementation Study","PEP-PROMIS","Inclusion Criteria:\n\n* ERCP in a patient with a native papilla (first ERCP) or repeat ERCP in a patient with previous failed cannulation attempt.\n* Age at least 18 years at the time of ERCP.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Previous papillotomy, papilla dilation, or sphincteroplasty.\n* Rendez-vous cannulation technique.\n* ERCP not performed due to insufficient patient cooperation.\n* ERCP terminated before cannulation due to sedation\u002Fanesthesia-related complications.\n* Failure to reach the Vater's or minor papilla (e.g. duodenal stenosis).\n* Acute biliary pancreatitis.\n* Altered anatomy that prevents reaching the papilla with a standard duodenoscope (e.g. Roux-en-Y).",{"count":91,"type":22},1000,"This is a prospective, observational (non-interventional), multicenter study that will look at how often inflammation of the pancreas (called post-ERCP pancreatitis, or PEP) occurs after an endoscopic procedure known as ERCP. The study will take place in several hospitals in Slovakia and Czechia and will include all patients who have this procedure during the study period.\n\nERCP is a common procedure used to treat problems in the bile ducts and pancreas. Although generally safe, it sometimes leads to PEP, which is the most frequent and potentially serious complication. Monitoring the rate of PEP helps doctors evaluate the overall quality of ERCP procedures, since patient safety is an important part of quality care.\n\nThe study will also look at how well hospitals follow current prevention guidelines from two major professional organizations-the European Society of Gastrointestinal Endoscopy (ESGE) and the American Society for Gastrointestinal Endoscopy (ASGE)-and how these prevention methods affect the risk of PEP. This information will help identify how closely real-world practice follows recommended preventive measures and provide new data about PEP rates in the region.",[94,95,29],"Pancreatitis, Acute","ERCP","2026-02-18",{"date":98,"type":35},"2026-02-20",{"date":100,"type":35},"2025-12-01",{"date":102,"type":22},"2026-05-31",{"name":104,"class":42},"Branislav Kuncak",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":18,"minAge":64,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":43},"100340829","phase-4-posaconazole-pharmacokinetics-in-patients-receiving-chemotherapy-or-stem-cell-transplants-100340829","NCT03717623","Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants","Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection","POPULAR","Inclusion Criteria:\n\n* Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Unable to give informed consent.",{"count":114,"type":22},100,[116],"PHASE4","The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.",[119,120,121,122,123,124,29],"Posaconazole","Pharmacokinetics","Invasive Candidiases","Invasive Aspergillosis","Invasive Mycosis","Fungal Infection","2025-02-26",{"date":127,"type":35},"2025-02-28",{"date":129,"type":35},"2019-08-01",{"date":131,"type":22},"2025-12-30",{"name":133,"class":42},"Melbourne Health",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":18,"minAge":64,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":43},"100573152","phase-3-apixaban-prophylaxis-for-prevention-of-left-ventricular-thrombus-following-anterior-myocardial-infarction-100573152","NCT06742567","Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction","Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction: An Open Label, Randomized Clinical Trial (POTAMI)","POTAMI","Inclusion Criteria:\n\n* Patients aged 18-65 years\n* Presenting with acute anterior STEMI\n* Severe LV dysfunction (EF\\\u003C35%) with antero-apical akinesis, dyskinesis, or aneurysm\n* WIHTOUT evidence of LV thrombus.\n\nExclusion Criteria:\n\n* Patients with previous anterior myocardial infarction or LAD revascularization procedures\n* Patients with cardiogenic shock\n* Patients with LV thrombus\n* Patients with advanced CKD (Cr \\> 2 and those on hemodialysis)\n* Recent ICH or major bleed requiring transfusion, low platelet counts \\\u003C100,000\n* History of recent CVA ( within past three months)\n* Patients with atrial fibrillation or other indications for chronic anticoagulation\n* Pregnant patients and those with hematological disorders","75 Years",{"count":144,"type":22},472,[146],"PHASE3","The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.",[149,150,29],"Acute Myocardial Infarction of Anterior Wall","Left Ventricular Thrombus",[152,153,154,155,156],"Acute myocardial infarction","severe left ventricular dysfunction","prevention of LV thrombus","DOAC","apixaban","2024-12-17",{"date":159,"type":35},"2024-12-19",{"date":161,"type":35},"2024-12-02",{"date":163,"type":22},"2025-11-30",{"name":165,"class":42},"National Institute of Cardiovascular Diseases, Pakistan"]